Disease and treatment characteristics for cases 1 and 2
| Disease/treatment characteristics* . | Case 1 . | Case 2 . | ||
|---|---|---|---|---|
| Predaratumumab . | Postdaratumumab . | Predaratumumab . | Postdaratumumab . | |
| Creatinine (mg/dL) | 1.9 | 1.4 | 3.1 | 2.0 |
| NT-ProBNP (pg/mL) | 2882 | 3568 | 1451 | 1660 |
| Troponin T (ng/mL) | 0.05 | <0.01 | 0.05 | 0.03 |
| Alkaline phosphatase (U/L) | 430 | 582 | 61 | 73 |
| Electrocardiogram | Pseudo-infarct pattern | NA | Normal | NA |
| Echocardiogram | ||||
| EF (%) | 64 | NA | 68 | NA |
| IVS (cm) | 1.6 | 1.1 | ||
| LV regional strain (normal is more negative than −18) | −7 | −23 | ||
| Prior treatment | ||||
| SCT | Yes | Yes | ||
| Bortezomib | Yes | Yes | ||
| IMiD | Yes | Yes | ||
| Dexamethasone | Yes | Yes | ||
| Carfilzomib | Yes | Yes | ||
| Disease/treatment characteristics* . | Case 1 . | Case 2 . | ||
|---|---|---|---|---|
| Predaratumumab . | Postdaratumumab . | Predaratumumab . | Postdaratumumab . | |
| Creatinine (mg/dL) | 1.9 | 1.4 | 3.1 | 2.0 |
| NT-ProBNP (pg/mL) | 2882 | 3568 | 1451 | 1660 |
| Troponin T (ng/mL) | 0.05 | <0.01 | 0.05 | 0.03 |
| Alkaline phosphatase (U/L) | 430 | 582 | 61 | 73 |
| Electrocardiogram | Pseudo-infarct pattern | NA | Normal | NA |
| Echocardiogram | ||||
| EF (%) | 64 | NA | 68 | NA |
| IVS (cm) | 1.6 | 1.1 | ||
| LV regional strain (normal is more negative than −18) | −7 | −23 | ||
| Prior treatment | ||||
| SCT | Yes | Yes | ||
| Bortezomib | Yes | Yes | ||
| IMiD | Yes | Yes | ||
| Dexamethasone | Yes | Yes | ||
| Carfilzomib | Yes | Yes | ||
EF, ejection fraction; IMiD, immunomodulatory drugs; IVS, interventricular septum thickness; LV, left ventricular; NA, not available; NT-ProBNP, N-terminal prohormone of brain natriuretic peptide.
The laboratory data in both cases from Mayo Clinic are presented, and the pre- and postdaratumumab values are separated by several months, as both patients were treated at different facilities.